Ian Cannon, MD
Family Medicine · Asheville, NCNPI 1376938274
Payments from drug & device makers
Across 139 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$533
- Abbott$362
- AstraZeneca$345
- Lilly USA, LLC$262
- Takeda Pharmaceuticals U.S.A., Inc.$208
- Novo Nordisk$108
- plus $557 from 15 others
Across 1 payment — averaging $125.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Indivior Inc.$125
What the payments were for
- Food & beverage$2,365100%
- Education$100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 36 | $533 |
| Abbott | 3 | $362 |
| AstraZeneca | 21 | $345 |
| Lilly USA, LLC | 17 | $262 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $208 |
| Novo Nordisk | 7 | $108 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $96 |
| Kowa Pharmaceuticals America, Inc. | 5 | $65 |
| Amgen | 4 | $58 |
| Eisai Inc. | 4 | $58 |
| Amarin Pharma, Inc. | 2 | $39 |
| AbbVie | 3 | $39 |
| Boehringer Ingelheim | 3 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Merck | 2 | $28 |
| Astellas Pharma US Inc | 1 | $24 |
| Phadia US Inc. | 1 | $20 |
| GSK | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Proclaim IPG$344
How this compares
$2,375 in reported general payments places this provider in the 80th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 88 | $85,412 |
| OzempicSemaglutide | 28 | $51,533 |
| FarxigaDapagliflozin Propanediol | 32 | $44,646 |
| XareltoRivaroxaban | 39 | $42,791 |
| JardianceEmpagliflozin | 30 | $38,055 |
| TrulicityDulaglutide | 21 | $30,934 |
| MyrbetriqMirabegron | 25 | $14,161 |
| TrintellixVortioxetine Hydrobromide | 17 | $13,658 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $12,750 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 48 | $10,809 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $8,768 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 13 | $7,031 |
| OxycontinOxycodone Hcl | 18 | $6,506 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 20 | $6,503 |
| Adacel TdapDiph,pertuss(Acell),tet Vac/Pf | 78 | $5,518 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo, Paxlovid | $533 | $93,343121 claims |
| Novo NordiskOzempic | $108 | $51,53328 claims |
| AstraZenecaFarxiga | $345 | $44,64632 claims |
| Johnson & JohnsonXarelto | $15 | $42,79139 claims |
| Boehringer IngelheimJardiance | $39 | $38,05530 claims |
| Lilly USA, LLCTrulicity | $262 | $30,93421 claims |
| GSKTrelegy Ellipta, Shingrix, Anoro Ellipta | $16 | $28,32879 claims |
| Astellas Pharma US IncMyrbetriq | $24 | $14,16125 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $208 | $13,65817 claims |
| AbbVieSynthroid | $39 | $2,49323 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Asheville
- Kimberly BaptisteAsheville$151K
- Jason CookAsheville$120K
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.